Obesity / Overweight / Acetaminophen · Phase 1 Trial

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

ClinicalTrials.gov · August 20, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 1 study registration for eloralintide, a novel agent intended to slow gastric emptying in overweight and obese participants. No results are posted in this registry record; the study is actively recruiting. The primary endpoints are pharmacokinetic measures of acetaminophen exposure, used as a surrogate marker of gastric function.

What was studied

Phase 1, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity, Overweight; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Eloralintide Cohort 1; Eloralintide Cohort 2; Eloralintide Cohort 3; Eloralintide Cohort 4. Compared with: Placebo — Placebo Comparator. n = 56. 2 sites: United States, Singapore.

Key findings

Safety

This is a registry record only; no results, efficacy data, or safety data are reported. Primary endpoints are pharmacokinetic surrogates, not clinical outcomes or weight loss.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

Phase 1 study of a novel gastrointestinal agent in a small, healthy volunteer population with pharmacokinetic endpoints; no efficacy or safety results reported in this registry record.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Acetaminophen Area Under the Concentration Versus Time Curve (AUC) (assessed at Baseline to Day 65); Acetaminophen Maximum Observed Concentration (Cₘₐₓ) (assessed at Baseline to Day 65); Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ) (assessed at Baseline to Day 65)

DesignPhase 1, Interventional, Randomized, Parallel, Double masking, Treatment purpose

PopulationObesity, Overweight; age from 18 Years; to 65 Years; accepts healthy volunteers

Sample size56

InterventionEloralintide Cohort 1; Eloralintide Cohort 2; Eloralintide Cohort 3; Eloralintide Cohort 4

ComparatorPlacebo — Placebo Comparator

Setting2 sites: United States, Singapore

Reported figures

Quoted from the source exactly as published.

Planned sample size56

Study phasePhase 1

Primary outcome measure 1Acetaminophen AUC, Baseline to Day 65

Primary outcome measure 2Acetaminophen Cₘₐₓ, Baseline to Day 65

Primary outcome measure 3Acetaminophen tₘₐₓ, Baseline to Day 65

Caveats

This is a registry record only; no results, efficacy data, or safety data are reported.
Primary endpoints are pharmacokinetic surrogates, not clinical outcomes or weight loss.
Recruitment status is active; study completion date and results posting timeline not stated.
Blinding method and detailed eligibility criteria not specified in the registry entry.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 1 design with placebo and positive control; registry record only, no results posted.

Directness

limited

Gastric emptying measured indirectly via acetaminophen PK; mechanism study, not clinical outcome.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

moderate

Placebo control present; blinding status not stated in registry record.

Sample adequacy

limited

56 participants estimated; typical Phase 1 size, underpowered for efficacy claims.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07738614). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 56 participants (ESTIMATED). Conditions: Obesity, Overweight. Interventions: DRUG: Eloralintide; DRUG: Placebo; DRUG: Acetaminophen. Primary outcome measures: Acetaminophen Area Under the Concentration Versus Time Curve (AUC) , Baseline to Day 65; Acetaminophen Maximum Observed Concentration (Cₘₐₓ) , Baseline to Day 65; Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ) , Baseline to Day 65. Brief summary: The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eli Lilly and CompanyObesityOverweightNCT07738614AcetaminophenEloralintide